Ozempic maker Novo Nordisk sets sights on hair-loss market

The condition is part of a list of areas, including addiction and menopause, where Novo sees potential overlap with either its core scientific expertise or the skills it's recently built in selling prescription drugs directly to consumers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/A7nF6lZ
via IFTTT

Read More

Root of the matter: What to know before trying professional hair treatments

Professional hair treatments can deliver smoother, shinier and more manageable hair, but their effects and risks vary depending on the treatment, formulation and existing hair health. This article explains how treatments such as keratin, relaxers and hair botox work, key questions to ask before a salon treatment, potential risks and why maintaining overall hair and scalp health matters beyond cosmetic results.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YEZ4asr
via IFTTT

Read More

Bharat Biotech is 'back in action' after Covid reset: Krishna Ella on TB vaccine, Nipah-Ebola shots, gene therapy, IPO plans & what’s next

Bharat Biotech is “back in action” after a two-year post-Covid reset, founder Krishna Ella says, with the company expanding beyond vaccines into cell and gene therapy and monoclonal antibodies. The vaccine maker is advancing programmes for TB, Nipah, Ebola, chikungunya, malaria, Zika and antimicrobial resistance, while exploring an IPO to fund new therapies and potential acquisitions. Ella says the company, which currently has around Rs 2,000 crore in revenue and is debt-free, is focused on accelerating innovation and preparing the next generation to lead its human and veterinary businesses.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/py9TwbP
via IFTTT

Read More

Medical device rules may get tougher: Govt plans new powers to stop manufacture, sale of unsafe, defective and spurious products, order destruction

The government is considering tougher medical device rules that could give regulators explicit powers to stop the manufacture, sale or distribution of unsafe, defective, substandard or spurious products and order their destruction. The proposed amendment to Rule 30(1) of the Medical Devices Rules, 2017, is aimed at strengthening enforcement, reducing ambiguity and ensuring potentially harmful devices are removed from circulation more quickly.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4ONHaMD
via IFTTT

Read More

Ichor Biologics seeks $80-100 million PE funding for minority stake sale

Ichor Biologics is seeking eighty to one hundred million dollars from private equity investors. The Hyderabad-based company operates in the specialized plasmatherapy segment. Promoters Ananda Reddy Sudini and Sujana Sudini hold significant stakes in the firm. Ichor manufactures therapeutic protein products derived from human plasma. The company's products serve various critical therapeutic areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dLQtXB1
via IFTTT

Read More

Unify Group marks ten years of success with The Grand Gala

Celebrating a decade of excellence, Unify Group hosted an impressive gala event that showcased its remarkable journey since its inception in 2016. Initially rooted in healthcare, the organization has boldly ventured into travel, logistics, and technology, paving the way for future innovations. The evening was a tribute to their significant milestones and a look ahead at the blossoming opportunities in their expanding portfolio.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XlzQewb
via IFTTT

Read More

Biocon arm gets positive EMA panel recommendation for breast cancerbiosimilar Pebrilzo

Biocon Biologics has received a positive recommendation from the European Medicines Agency’s CHMP for its Pertuzumab biosimilar, Pebrilzo, for HER2-positive breast cancer. The European Commission will take the final decision on marketing authorisation across the EU.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8XivGI1
via IFTTT

Read More